Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health challenge, particularly in developing countries. This article aims to provide an updated perspective on the diagnosis and treatment of this infectious disease.
Diagnosis of enteric fever primarily relies on clinical presentation and microbiological confirmation. Blood culture is the gold standard, with sensitivity rates of 40-80%. However, it requires a sophisticated laboratory and takes time. The Widal test, though widely used due to its simplicity and cost-effectiveness, has limitations in specificity and sensitivity. Recent advances include nucleic acid amplification tests (NAATs), which offer faster results with high sensitivity and specificity, albeit at a higher cost.
Antibiotic therapy is the mainstay of enteric fever treatment. The choice of antibiotic should be guided by local susceptibility patterns. Fluoroquinolones were once the drug of choice, but increasing resistance has led to a shift towards azithromycin and third-generation cephalosporins like ceftriaxone. Resistance to multiple drugs is a growing concern, emphasizing the importance of susceptibility testing. Vaccination and improvements in sanitation and hygiene are crucial preventive measures.
The major challenges in managing enteric fever include increasing antimicrobial resistance, limited diagnostic tools in resource-poor settings, and lack of effective vaccines. Future strategies should focus on developing rapid, cost-effective diagnostic tests, new antibiotics, and more effective vaccines. Integration of genomic surveillance into public health programs can help track resistance patterns and guide treatment strategies.
In conclusion, enteric fever continues to be a significant health burden. A comprehensive approach to its diagnosis and treatment, including the development and implementation of rapid diagnostic tools, effective antibiotics, and vaccines, is essential. Continued research and surveillance are crucial to address the emerging challenges in enteric fever management.
1.
Does Maintenance Therapy Extend Life in mCRC?
2.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
3.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
4.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
5.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
1.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
2.
Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers
3.
Personalized Survivorship Navigation in Precision Cancer Care
4.
Hematopoietic Stem Cell Exhaustion in Blood Disorders
5.
Hematopoietic Clonal Competition in Blood Disorders
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Advances in Modern Cancer Treatment
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Early Warning Signs of Cancer
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation